KBC Group NV Has $47.96 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

KBC Group NV lowered its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 27.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 647,842 shares of the medical research company’s stock after selling 248,320 shares during the period. KBC Group NV’s holdings in Edwards Lifesciences were worth $47,959,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter worth about $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $32,000. Avior Wealth Management LLC increased its position in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares in the last quarter. Peoples Bank KS bought a new position in Edwards Lifesciences in the 3rd quarter valued at approximately $40,000. Finally, Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $46,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $69.21 on Tuesday. The firm has a 50 day moving average of $72.33 and a 200-day moving average of $70.36. The company has a market cap of $40.82 billion, a price-to-earnings ratio of 9.99, a price-to-earnings-growth ratio of 3.54 and a beta of 1.11. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock valued at $2,195,180 over the last ninety days. 1.29% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research reports. Evercore ISI dropped their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective for the company. in a report on Thursday, January 16th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $78.48.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.